Skip to content
AnalystLens

Regeneron Pharmaceuticals 8-K Report, Financial Results (Jul 6, 2026)

Reports
Earnings & Results
Filing Date
Filed July 6, 2026
Period End
July 6, 2026
Security
REGN
In the record · 2016–202610-K1110-Q338-K115

REGN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 115 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’17Jan ’17
  2. Material agreement8-K · May ’19May ’19
  3. Material agreement8-K · Sep ’21Sep ’21
  4. Leadership change8-K · Jan ’24Jan ’24

01—Abstract

Summary

Summary of the 8-K filed July 6, 2026. Cited figures are marked; the original filing is the authoritative source.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 6, 2026, providing a preliminary update on its expected financial results for the second quarter of 2026.

The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $127 milliona. This charge is primarily related to up-front and opt-in payments made under various collaboration and licensing agreements. The estimated impact of this acquired IPR&D charge is a reduction of approximately $1.00 per diluted share on both Generally Accepted Accounting Principles (GAAP) and non-GAAP net income for the second quarter.

Regeneron cautions that these are preliminary estimates and subject to change as financial closing procedures are completed, and actual results may differ. Investors should note that IPR&D charges are inherently unpredictable due to the uncertain nature of future collaborations and development milestones.

02—Key points

Key Highlights

  1. Regeneron anticipates a pre-tax acquired IPR&D charge of approximately $127 million for Q2 2026.
  2. This charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $1.00.
  3. The IPR&D charge is associated with collaboration and licensing agreements, including up-front and opt-in payments.
  4. The company emphasizes that these are preliminary, unaudited estimates and actual results may vary.
  5. Regeneron does not forecast IPR&D charges due to their inherent uncertainty in timing and magnitude.
  6. The filing includes standard forward-looking statement disclaimers, noting risks and uncertainties.
  7. A reconciliation of non-GAAP financial measures to GAAP is provided, highlighting management's use of non-GAAP data for operational assessment.

03—Questions

Frequently Asked Questions

  1. What is the primary reason for the expected charge in Regeneron's Q2 2026 results?

    The primary reason for the expected charge is approximately $127 million related to acquired in-process research and development (IPR&D) from collaboration and licensing agreements. This includes up-front and opt-in payments made by the company.

  2. How will this IPR&D charge affect Regeneron's earnings per share?

    The acquired IPR&D charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $1.00 for the second quarter of 2026.

  3. Are these financial results finalized?

    No, these are preliminary, unaudited estimates. Regeneron's financial results for the second quarter of 2026 are not yet finalized and are subject to the company's financial statement closing procedures. Actual results may differ from these estimates.

  4. Why doesn't Regeneron forecast IPR&D charges?

    Regeneron does not forecast acquired IPR&D charges because of the inherent uncertainty regarding the future occurrence, magnitude, and timing of these transactions, which are often tied to the success and progression of collaborative research and development efforts.

04—Continue

← View all 8-K filings